Acupuncture vs sham
Major adverse events · Adults with overactive bladder (OAB)
1 finding from 1 review
- no estimate extracted5 studies · 236 participantsLow
Findings
What do systematic reviews say?
4,918 questions · 5,537 findings · 1,803 reviews
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Any of the interventions (CR, SE, SW, sealing with sealant materials, Hall Technique, or NRCC) vs Each other, placebo, or no treatment
Adverse events (any type) and safety of sealant · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
The review found no eligible studies for this question.
1 finding from 1 review
- None of the studies reported adverse effects.0 studiesNo studies found
Topical prophylaxis vs no topical prophylaxis
Dropouts due to adverse events · adults receiving mechanical ventilation for at least 48 hours
It is very uncertain whether topical prophylaxis changes dropouts due to adverse events compared with no topical prophylaxis (very low certainty).
1 finding from 1 review
- Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical… 2021 · Cochrane Headline outcomes onlyRR 2.2 [0.57, 8.54]7 studies · 1323 participantsVery low
Topical plus systemic prophylaxis vs placebo or no treatment
Dropouts due to adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in dropouts due to adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
- Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical… 2021 · Cochrane Headline outcomes onlyRR 1.06 [0.3, 3.76]4 studies · 1287 participantsLow
Fluoxetine vs placebo
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
- Second‐generation antidepressants for treatment of seasonal affective disorder 2021 · Cochrane Headline outcomes onlyRR 1.07 [0.95, 1.21]1 study · 68 participantsVery low
Lamotrigine vs phenobarbital
Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether lamotrigine changes proportion with adverse events compared with phenobarbital (very low certainty).
1 finding from 1 review
- RR 0.68 [0.3, 1.53]1 study · 57 participantsVery low
Levetiracetam vs lamotrigine
Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with adverse events compared with lamotrigine (very low certainty).
1 finding from 1 review
- RR 0.65 [0.25, 1.74]1 study · 67 participantsVery low
Levetiracetam vs phenobarbital
Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with adverse events compared with phenobarbital (very low certainty).
1 finding from 1 review
- RR 0.44 [0.18, 1.07]1 study · 66 participantsVery low
Sotrovimab vs placebo
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.26 [0.12, 0.6]1 study · 868 participantsLow
Regdanvimab vs placebo
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 2.62 [0.52, 13.12]1 study · 215 participantsLow
Meropenem vs usual care
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).
1 finding from 1 review
- RR 1.54 [0.9, 2.66]1 study · 271 participantsVery low
Vancomycin plus gentamicin vs vancomycin plus aztreonam
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
- RR 0.65 [0.2, 2.13]1 study · 81 participantsVery low
Cefazolin plus amikacin vs vancomycin plus amikacin
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).
1 finding from 1 review
- RR 0.7 [0.29, 1.66]1 study · 109 participantsVery low
Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with flucloxacillin and gentamicin (very low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.82]1 study · 28 participantsVery low
Cloxacillin plus amikacin vs cefotaxime plus gentamicin
Serious adverse events maximum · newborns with late‐onset sepsis
It is very uncertain whether cloxacillin plus amikacin changes serious adverse events maximum compared with cefotaxime plus gentamicin (very low certainty).
1 finding from 1 review
- RR 0.5 [0.17, 1.48]1 study · 90 participantsVery low
Piperacillin vs ampicillin plus amikacin
Serious adverse events maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
1 finding from 1 review
- RR 0.62 [0.35, 1.1]1 study · 396 participantsVery low
Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin
Serious adverse events maximum · neonates with early‐onset sepsis
1 finding from 1 review
- no estimate extracted1 study · 55 participantsVery low
Ampicillin plus gentamicin vs penicillin plus gentamicin
Serious adverse events maximum · neonates with early‐onset sepsis
It is very uncertain whether ampicillin plus gentamicin changes serious adverse events maximum compared with penicillin plus gentamicin (very low certainty).
1 finding from 1 review
- RR 0.93 [0.72, 1.21]1 study · 283 participantsVery low
Piperacillin plus tazobactam vs amikacin
Serious adverse events maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
1 finding from 1 review
- RR 0.97 [0.15, 6.41]1 study · 59 participantsVery low
Ticarcillin plus clavulanic acid vs piperacillin plus gentamicin
Serious adverse events maximum · neonates with early‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
1 finding from 1 review
- RR 0.75 [0.19, 2.9]1 study · 72 participantsVery low